The aim of the study was to determine the effect of the inhibitor of janus kinase–baricitinib ("
Olumiant") on the course of COVID-19. This drug baricitinib is able to suppress the systemic …

Pneumonia associated with coronavirus disease 2019 (COVID-19) has been accounted for
high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of …

A patient with COVID-19-related severe respiratory failure, with insufficient response to an
antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy …

Objectives To analyse the effectiveness and safety of baricitinib for severe COVID-19 in
cytokine storm syndrome based on its potential role as an anti-inflammatory …

Objectives Several clinical trials have evaluated the efficacy and safety of baricitinib in
COVID-19 patients. Recently, there have been reports on critical patients, which are different …

Purpose Hyperinflammation in severe COVID-19 infection increases the risk of respiratory
failure and one of the cogent reasons of mortality associated with COVID-19. Baricitinib, a …

In December 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly …

The benefits of baricitinib in coronavirus disease‐2019 are inadequately defined. We
performed a systematic review and meta‐analysis of studies of baricitinib to determine its …

The article evaluates the results of Riamilovir use in treatment of patients with a moderate
form of the disease caused by a new strain of the SARS-CoV-2 virus. It was found that the …

Background: This study aimed to investigate the efficacy and safety of baricitinib in patients
with severe coronavirus disease 2019 (COVID-19). Methods: Databases were searched for …